drugset
drugset / Trial / NCT06799884

A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives

NCT06799884 ↗

Phase 1 Completed 19 enrolled Idorsia Pharmaceuticals Ltd.
Non-randomizedSequentialOpen-labelOther

Summary

The goal of this clinical trial is to learn if drug aprocitentan has an effect on hormonal contraceptives in healthy female volunteers. The main question it aims to answer is: Does aprocitentan modify the fate of hormonal contraceptives in the body? Trial participants will: * Take a single dose of hormonal contraceptives (fixed combination) alone * Take aprocitentan every day for 2 weeks * Take a single dose of the same hormonal contraceptives at the same time as the 10th administration of aprocitentan.

Timeline

Start
2025-01-18
Primary completion
2025-02-21
Completion
2025-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprocitentan Small molecule 25 mg Oral
Subject Levonorgestrel Small molecule 100 ug Oral
Subject ethinyl estradiol Small molecule 20 ug Oral

Indications

No indication recorded.